Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 9/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.35 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29665757 | 1.00 | MKNK2 (0.41) | MKNK2PARP1MKNK1SLC22A12ENPP1 | |
| SCHEMBL30319582 | 0.84 | PARP1 (0.58) | MKNK2PARP1MKNK1SLC22A12 | |
| SCHEMBL30564558 | 0.84 | NOTUM (0.43) | MKNK2PARP1MKNK1SLC22A12CYP1A2 | |
| Hydrochloric Acid SCHEMBL30319541 | 0.83 | PARP1 (0.57) | MKNK2PARP1MKNK1SLC22A12 | |
| SCHEMBL30172790 | 0.80 | MKNK2 (0.40) | MKNK2PARP1MKNK1SLC22A12CYP3A4 | |
| SCHEMBL31365162 | 0.80 | ENPP3 (0.38) | MKNK2PARP1MKNK1ENPP1ENPP3 | |
| SCHEMBL30358558 | 0.80 | PARP1 (0.40) | MKNK2PARP1MKNK1SLC22A12ENPP1 | |
| Hydrochloric Acid SCHEMBL30358557 | 0.79 | PARP1 (0.39) | MKNK2PARP1MKNK1SLC22A12ENPP1 | |
| SCHEMBL27869342 | 0.77 | PIK3CD (0.45) | MKNK2PARP1EGFRIRAK4 | |
| Hydrochloric Acid SCHEMBL30358580 | 0.76 | MKNK2 (0.39) | MKNK2PARP1MKNK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658290-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-15 | — | — | EP | claimed |
| US-7338957-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-03-04 | — | — | US | claimed |
| JP-2007504159-A | — | — | 2007-03-01 | — | — | JP | claimed |
| EP-1658290-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-24 | — | — | EP | claimed |
| WO-2005039486-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-05-06 | — | — | WO | claimed |
| WO-2023067387-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF DERMAL AND OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-04-27 | — | — | WO | disclosed |
| EP-3026052-A9 | PREPARATION OF DEUTERATED PIPERIDINE INHIBITORS OF JANUS KINASE 3 | Auspex Pharmaceuticals, Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-3026052-A1 | PREPARATION OF DEUTERATED PIPERIDINE INHIBITORS OF JANUS KINASE 3 | Auspex Pharmaceuticals, Inc. (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-2421867-B1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | AUSPEX PHARMACEUTICALS LLC (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-1658290-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-15 | — | — | EP | disclosed |
| US-20080108616-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-05-08 | — | — | US | disclosed |
| US-7338957-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-03-04 | — | — | US | disclosed |
| EP-1658290-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005039486-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108616-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | LCK, FYN, BMX | MKNK2 82/4885PARP1 4263/4885MKNK1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.